

AMENDED CLAIMS

received by the International Bureau on 29 June 2005 (29.06.2005): original claims 1-17 have been replaced by amended claims 1-15 (4 pages).

+

Statement

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. A method for detecting the presence or absence of a variant nucleotide in at least two SNP sites associated with thrombosis, said SNP sites selected from the group consisting of Factor V Leiden G1691A, Prothrombin (Factor II) G20210A, MTHFR C677T, MTHFR A1298C, Factor XIII G4377T, and tissue factor plasma inhibitor (TFPI) C536T, the method comprising the steps of;

a) amplifying regions of DNA containing the at least two SNP sites to form amplified DNA products;

b) hybridizing at least two tagged allele specific extension primers to a complementary target sequence in the amplified DNA products, wherein each tagged allele specific extension primer has a 3'-end hybridizing portion capable of hybridizing to the amplified DNA, and wherein the 3' end hybridizing portion of the at least two tagged allele specific extension primers comprise a sequence selected from the group consisting of bases 25 and up of SEQ ID NO: 1 to SEQ ID NO: 12, and a 5'-end tag portion complementary to a corresponding probe sequence, the terminal nucleotide of the 3' end hybridizing portion being either complementary to a suspected variant nucleotide or to the corresponding wild type nucleotide of the SNP site;

c) extending the at least two tagged allele specific extension primers, using labelled nucleotides, if the terminal nucleotide of the 3' end hybridizing portion is a perfect match to an allele of one of the SNP sites in the amplified DNA products;

d) hybridizing the at least two tagged allele specific extension primers to the corresponding probe sequence and detecting the presence of labelled extension products.

2. The method of claim 2 wherein the 5'-end tag portions of the at least two tagged allele specific primers comprises a sequence selected from the group consisting of bases 1 to 24 of SEQ ID NO: 1 to SEQ ID NO: 12.

3. The method of claim 1 wherein the probe sequence is coupled to a solid support.

4. The method of claim 3 wherein the solid support is selected from the group consisting of beads, spectrally coded beads, and a chip based microarray.

5. The method of claim 1 wherein the step of amplifying is conducted using a set of PCR amplification primers, said set comprising at least two pairs of PCR primers selected from the group of pairs consisting of:
SEQ ID NO: 13 and SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, SEQ ID NO: 21 and SEQ ID NO: 22, and SEQ ID NO: 23 and SEQ ID NO: 24.

6. A method for detecting the presence or absence of a variant nucleotide in at least two SNP sites associated with thrombosis, said SNP sites selected from the group consisting of Factor V Leiden G1691A, Prothrombin (Factor II) G20210A, MTHFR C677T, MTHFR A1298C, Factor XIII G4377T, and tissue factor plasma inhibitor (TFPI) C536T, the method comprising the steps of;

a) amplifying regions of DNA containing the at least two SNP sites to form amplified DNA products;

b) hybridizing at least two tagged allele specific extension primers to a complementary target sequence in the amplified DNA products, wherein the at least two tagged allele-specific extension primers are selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 12, each tagged allele specific extension primer having a 3'-end hybridizing portion capable of hybridizing to the amplified DNA, and a 5'-end tag portion complementary to a corresponding probe sequence, the terminal nucleotide of the 3' end hybridizing portion being either complementary to a suspected variant nucleotide or to the corresponding wild type nucleotide of the SNP site;

c) extending the at least two tagged allele specific extension primers, using labelled nucleotides, if the terminal nucleotide of the 3' end hybridizing portion is a perfect match to an allele of one of the SNP sites in the amplified DNA products;

d) hybridizing the at least two tagged allele specific extension primers to the corresponding probe sequence and detecting the presence of labelled extension products.

7. The method of claim 6 wherein the probe sequence is coupled to a solid support.
8. The method of claim 7 wherein the solid support is selected from the group consisting of beads, spectrally coded beads, and a chip based microarray.
9. The method of claim 6 wherein the step of amplifying is conducted using a set of PCR amplification primers, said set comprising at least two pairs of PCR primers selected from the group of pairs consisting of
SEQ ID NO: 13 and SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16, SEQ ID NO: 17 and
SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, SEQ ID NO: 21 and SEQ ID NO: 22, and
SEQ ID NO: 23 and SEQ ID NO: 24.
10. A kit for use in detecting the presence or absence of a variant nucleotide in at least two SNP sites associated with thrombosis, said SNP sites selected from the group consisting of Factor V Leiden G1691A, Prothrombin (Factor II) G20210A, MTHFR C677T, MTHFR A1298C, Factor XIII G4377T, and tissue factor plasma inhibitor (TFPI) C536T, said kit comprising a set of at least two tagged allele specific extension primers wherein each tagged allele specific extension primer has a 3'-end hybridizing portion including a 3' terminal nucleotide being either complementary to a suspected variant nucleotide or to the corresponding wild type nucleotide of one of the SNP sites and a 5'-end tag portion complementary to a corresponding probe sequence, and wherein the at least two tagged allele-specific extension primers are selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 12.
11. The kit of claim 10 further comprising a set of PCR amplification primers for amplifying regions of DNA containing the at least two SNP sites, said set comprising at least two pairs of PCR primers selected from the group of pairs consisting of
SEQ ID NO: 13 and SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16, SEQ ID NO: 17 and
SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, SEQ ID NO: 21 and SEQ ID NO: 22, and
SEQ ID NO: 23 and SEQ ID NO: 24.
12. The kit of claim 10 further comprising a set of probes.

13. The kit of claim 12 wherein the set of probes are coupled to a support.

14. A kit for use in detecting the presence or absence of a variant nucleotide in at least two SNP sites associated with thrombosis, said SNP sites selected from the group consisting of Factor V Leiden G1691A, Prothrombin (Factor II) G20210A, MTHFR C677T, MTHFR A1298C, Factor XIII G4377T, and tissue factor plasma inhibitor (TFPI) C536T, said kit comprising a set of PCR amplification primers for amplifying regions of DNA containing the at least two SNP sites, said set comprising at least two pairs of PCR primers selected from the group of pairs consisting of:
SEQ ID NO: 13 and SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, SEQ ID NO: 21 and SEQ ID NO: 22, and SEQ ID NO: 23 and SEQ ID NO: 24.

15. The kit of claim 14 further comprising a set of at least two tagged allele specific extension primers wherein each tagged allele specific extension primer has a 3'-end hybridizing

IN THE INTERNATIONAL BUREAU OF WIPO

Applicant: TM Bioscience Corporation
Serial No.: PCT/CA2004/001974
Title: Method of Detecting Mutations Associated with Thrombosis
Filed: November 17, 2004
Our Ref.: 53436/00145

June 29, 2005

The International Bureau of WIPO
34 Chemin des Colombettes
1211 Geneva 20
Switzerland

STATEMENT UNDER ARTICLE 19(1)
(Rule 46.4)


Dear Sir:

Concurrently with the filing of an Amendment under Article 19 of the PCT, Applicant submits the following statement pursuant to Rule 46.4.

Remarks Concerning Amendments Made

Applicant submits that the amendments made to the claims of the present application serve to distinguish same from the prior art cited in the International Search Report and to more accurately claim the present invention. Previous claims 1 to 17 have been replaced with new claims 1 to 15.

The Office is requested to enter present amendment to the claims and is invited to contact the undersigned should any further information be required.

Respectfully submitted,
BLAKE, CASSELS & GRAYDON LLP
Agents for the Applicant
per: 

Santosh K. Chari
Tel: 416-863-3166
SKC/CRD
21423602.1